This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stocks Slide on Eurozone Worries, Apple

Over the weekend, a People's Bank of China official warned that the country's slowing economy could extend into next year.

A dearth of guidance from Spain on its bailout plans also added to the global anxiety.

In addition, Standard & Poor's lowered its full-year economic growth outlook for the Asia Pacific region. At home, the general business activity index from the Dallas Fed Manufacturing Survey remained slightly negative but edged up to -0.9 from -1.6, and the Chicago Fed National Activity Index decreased to -0.87 in August from -0.12 in July led by declines in production-related indicators.

The FTSE in London closed down 0.24% and the DAX in Germany settled off 0.52%. Hong Kong's Hang Seng index finished down by 0.19% on Monday and the Nikkei in Japan settled behind by 0.45%.

The benchmark 10-year Treasury gained 13/32, pushing the yield down to 1.711%. The greenback rose 0.20%, according to the dollar index.

November crude oil futures lost 96 cents to settle at $91.93 a barrel while December gold futures dropped $13.40 to settle at $1,764.60 an ounce.

In corporate news, Facebook (FB - Get Report) shares dropped more than 9% after Barron's questioned the company's valuation over the weekend.

Lennar (LEN), the homebuilder, posted fiscal third-quarter earnings of 40 cents a share. Revenue in the quarter rose 34% to $1.1 billion. Shares lost 1.5%.

Google ( GOOG ) shares hit an all-time intraday high at $747.28 after Citi noted that the internet giant's streamlining of its Motorola Mobility business was grabbing the attention of the investment community. Shares popped 2.1% at final check.

Questcor Pharmaceuticals ( QCOR ) shares tumbled 36.7% after saying that the company is under a U.S. government investigation involving its promotional practices and that the firm plans to cooperate in the process.

Peregrine Pharmaceuticals ( PPHM ) shares plunged 78.5% after the company said that it discovered major discrepancies between some patient sample test results and patient treatment code assignments during the course of preparing for a meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase 2 trial of bavituximab in second-line non-small cell lung cancer.




--Written by Andrea Tse and Joe Deaux in New York.



>To contact the writer of this article, click here: Andrea Tse.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%
TSLA $206.79 0.00%
YHOO $44.45 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs